[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100572996":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":11,"centralContacts":19,"locations":25,"responsibleParty":90,"collaborators":11,"id":92,"slug":11,"hasResults":93,"nctId":94,"briefTitle":95,"officialTitle":96,"acronym":11,"eligibilityCriteria":97,"healthyVolunteers":93,"sex":98,"minAge":99,"maxAge":11,"enrollmentInfo":100,"targetDuration":11,"studyType":103,"phases":104,"briefSummary":106,"conditions":107,"keywords":11,"overallStatus":28,"whyStopped":11,"lastUpdateSubmitDate":109,"lastUpdatePostDateStruct":110,"startDateStruct":113,"completionDateStruct":115,"leadSponsor":117,"locationsCount":118},{"fullName":5,"class":6},"Otsuka Pharmaceutical Development & Commercialization, Inc.","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Sibeprenlimab","EXPERIMENTAL",null,[13],"Drug: Sibeprenlimab",[15],{"type":16,"name":9,"description":17,"armGroupLabels":18,"otherNames":11},"DRUG","Sibeprelimab SC (Period 1)\n\nSibeprelimab SC (Period 2)",[9],[20],{"name":21,"role":22,"phone":23,"phoneExt":11,"email":24},"Otsuka Call Center","CONTACT","844-687-8522","Otsuka-ProfessionalServices@otsuka-us.com",[26,41,53,65,77],{"facility":27,"status":28,"city":29,"state":30,"zip":31,"country":32,"cosmosGeoPoint":33,"geoPoint":38,"contacts":39},"Clinical Research Site 330","RECRUITING","Denver","Colorado","80230","United States",{"type":34,"coordinates":35},"Point",[36,37],-104.9847,39.73915,{"lat":37,"lon":36},[40],{"name":21,"role":22,"phone":11,"phoneExt":11,"email":11},{"facility":42,"status":28,"city":43,"state":44,"zip":45,"country":32,"cosmosGeoPoint":46,"geoPoint":50,"contacts":51},"Clinical Research Site 369","Boston","Massachusetts","21144",{"type":34,"coordinates":47},[48,49],-71.05977,42.35843,{"lat":49,"lon":48},[52],{"name":21,"role":22,"phone":11,"phoneExt":11,"email":11},{"facility":54,"status":28,"city":55,"state":56,"zip":57,"country":32,"cosmosGeoPoint":58,"geoPoint":62,"contacts":63},"Clinical Research Site 374","Dakota Dunes","South Dakota","57409",{"type":34,"coordinates":59},[60,61],-96.48642,42.48749,{"lat":61,"lon":60},[64],{"name":21,"role":22,"phone":11,"phoneExt":11,"email":11},{"facility":66,"status":28,"city":67,"state":68,"zip":69,"country":32,"cosmosGeoPoint":70,"geoPoint":74,"contacts":75},"Clinical Research Site 324","Houston","Texas","77054",{"type":34,"coordinates":71},[72,73],-95.36327,29.76328,{"lat":73,"lon":72},[76],{"name":21,"role":22,"phone":11,"phoneExt":11,"email":11},{"facility":78,"status":28,"city":79,"state":80,"zip":81,"country":82,"cosmosGeoPoint":83,"geoPoint":87,"contacts":88},"Clinical Research Site 305","Scarborough Village","Ontario","M1H 3G4","Canada",{"type":34,"coordinates":84},[85,86],-79.22124,43.73899,{"lat":86,"lon":85},[89],{"name":21,"role":22,"phone":11,"phoneExt":11,"email":11},{"type":91,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100572996",false,"NCT06740526","Trial of the Impact of Sibeprenlimab on Immunoglobulin A Nephropathy Kidney Tissue","A Phase 2b, Multicenter, Open-label, Single-arm Trial to Evaluate the Impact of Sibeprenlimab on Kidney Histopathology Through Repeat Kidney Biopsies in Adolescents and Adults With Immunoglobulin A Nephropathy","Inclusion Criteria:\n\n1. Participants must be at least 16 years of age or older at the time of signing the informed consent\u002Fassent.\n2. Source-verified kidney biopsy confirmed diagnosis of IgAN.\n3. Participant has estimated glomerular filtration rate (eGFR) \\> 45 mL\u002Fmin\u002F1.73 m2 using serum creatinine (Chronic Kidney Disease-Epidemiology Collaboration \\[CKD EPI\\] creatinine eGFR 2021 equation for those 18 years and older; Chronic Kidney Disease in Children under age 25 \\[CKiD U25\\] eGFR equation for those younger than 18 years)\n\nExclusion Criteria:\n\n1. Participants who are breast-feeding and\u002For who have a positive pregnancy test result prior to receiving sibeprenlimab.\n2. Participant has coexisting chronic kidney disease, other than IgAN.\n3. Participant has a serum IgG value \\\u003C600 mg\u002FdL at screening.\n4. Participant is currently receiving or has received within 24 weeks prior to the firstdose of sibeprenlimab, systemic corticosteroids or immunosuppression (note:\n\n   topical, ophthalmic, rectal, intra-articular, inhaled corticosteroids are allowed).\n5. Participant has uncontrolled hypertension (defined as systolic blood pressure \\> 140 mmHg or diastolic blood pressure \\> 90 mmHg).\n6. Participants who would be likely to require prohibited concomitant therapy during the trial.","ALL","16 Years",{"count":101,"type":102},25,"ESTIMATED","INTERVENTIONAL",[105],"PHASE2","This is a phase 2b open-label trial to characterize histopathological biomarkers of disease in immunoglobulin A nephropathy (IgAN) and demonstrate potential changes in response to sibeprenlimab.",[108],"IgA Nephropathy","2025-04-04",{"date":111,"type":112},"2025-04-06","ACTUAL",{"date":114,"type":112},"2024-11-19",{"date":116,"type":102},"2029-04-17",{"name":5,"class":6},5]